Showing 2,045 news articles about PrEP

Filters Content type: Editors' picks Topic: PrEP

Pre-exposure prophylaxis involves people who do not have HIV taking antiretroviral drugs when they are at risk of exposure to HIV in order to prevent infection. The drugs are usually taken as pills (oral PrEP).

PrEP policies & guidelines

US: Government-Mandated PrEP Coverage Mostly Survives Appeals Court Ruling; Threats Still Loom

Editor's pick
TheBody
27 June 2024
Adherence

Overcoming the Challenges of Adhering to Injectable ART and PrEP

Editor's pick
Infectious Disease Special Edition
26 June 2024
PrEP programmes & uptake

How PrEP4Teens Constructed a Rigorously Researched, Teen-Led Sexual-Health Program

Editor's pick
TheBodyPro
26 June 2024
People & personal stories

Moupali Das, M.D., M.P.H., Designed the Lenacapavir Study With Black and Brown Girls in Mind

Editor's pick
TheBody
25 June 2024
Injectable & long-acting PrEP

Statement From The Gilead’s Purpose 1 Global Community Accountability Board, The African Women’s Prevention Community Accountability Board, Our Partners And Community Partners

Editor's pick
African Women’s Prevention Community Accountability Board
24 June 2024
PrEP policies & guidelines

Appeals court finds 'Obamacare' pillar unconstitutional in suit over HIV-prevention drug

Editor's pick
NBC News
24 June 2024
Vaginal rings & topical PrEP

Vaginal Ring for PrEP Found Effective and Safe During Pregnancy

Editor's pick
Infectious Disease Special Edition
24 June 2024
Injectable & long-acting PrEP

Unitaid calls for accelerated global access to long-acting HIV prevention drug lenacapavir after positive trial results

Editor's pick
Unitaid
21 June 2024
Injectable & long-acting PrEP

ICWEA Statement on Gilead’s announcement of twice-yearly Lenacapavir (LEN) for HIV prevention.

Editor's pick
International Community of Women living with HIV Eastern Africa
21 June 2024
Injectable & long-acting PrEP

Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention

Editor's pick
Gilead Sciences press release
21 June 2024
Pharmaceutical industry

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Editor's pick
FiercePharma
21 June 2024
Injectable & long-acting PrEP

Treatment Action Group Statement on Lenacapavir PrEP: Getting from Efficacy to Access Requires Generic Licensing and Cost Reductions

Editor's pick
Treatment Action Group
21 June 2024
Injectable & long-acting PrEP

“Long overdue long-acting products” A call to action to accelerate access to lenacapavir!

Editor's pick
AfroCAB
21 June 2024
Injectable & long-acting PrEP

Landmark Trial in South Africa and Uganda Finds Twice Yearly HIV Prevention Injection Safe and Highly Effective

Editor's pick
AVAC
20 June 2024
Injectable & long-acting PrEP

Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

Editor's pick
Gilead Sciences press release
20 June 2024
HIV prevention policy

HIV prevention drug uptake is slow. Can offering choices change that?

Editor's pick
Devex (requires free registration)
20 June 2024
Men who have sex with men (MSM)

Local Laws, Policies, and State-Level Politics Are Associated With PrEP Use Among Younger LGBTQ+ People

Editor's pick
TheBodyPro
18 June 2024
Injectable & long-acting PrEP

Zambia is the first country in Africa to roll out long-acting, injectable HIV prevention

Editor's pick
Gavi
5 June 2024
Injectable & long-acting PrEP

U.S. Clinical Trials Begin for Twice-Yearly HIV Prevention Injection

Editor's pick
National Institute of Allergy and Infectious Diseases
4 June 2024
PrEP programmes & uptake

Do US Health Insurers Offer Clear Info on Covering PrEP to Prevent HIV?

Editor's pick
POZ
29 May 2024
Prisoners

PrEP Program in Jails Can Be Successfully Started, but Many Barriers Remain, Rhode Island Study Finds

Editor's pick
TheBodyPro
27 May 2024
PrEP programmes & uptake

How can we help more young men access PrEP?

Editor's pick
Be In The Know
23 May 2024
Injectable & long-acting PrEP

Health Canada approves Apretude, the first long-acting injectable for HIV prevention

Editor's pick
CATIE
16 May 2024
Injectable & long-acting PrEP

UK: New cabotegravir formulations approved to help prevent HIV-1 infection in adults and adolescents

Editor's pick
Medicines and Healthcare products Regulatory Agency (MHRA)
6 May 2024